Parallax Volatility Advisers, L.P. Iovance Biotherapeutics, Inc. Call Options Transaction History

Parallax Volatility Advisers, L.P.

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	BUY	$7.59 - $17.47 $258,060 - $593,980	34,000 New	34,000 $503,000
Q3 2022 Nov 14, 2022	BUY	$9.53 - $13.11 $1.31 Million - $1.8 Million	137,500 New	137,500 $1.32 Million
Q3 2021 Nov 15, 2021	SELL	$20.35 - $26.63 $17 Million - $22.2 Million	-833,100 Reduced 81.41%	190,300 $4.69 Million
Q2 2021 Aug 16, 2021	BUY	$16.33 - $33.07 $15.6 Million - $31.7 Million	957,100 Added 1443.59%	1,023,400 $26.6 Million
Q1 2021 May 14, 2021	BUY	$28.67 - $52.59 $295,301 - $541,677	10,300 Added 18.39%	66,300 $2.1 Million
Q4 2020 Feb 16, 2021	SELL	$28.04 - $50.26 $291,616 - $522,704	-10,400 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$28.04 - $50.26 $1.57 Million - $2.81 Million	56,000 New	56,000 $2.6 Million
Q3 2020 Nov 13, 2020	SELL	$27.75 - $36.3 $466,200 - $609,840	-16,800 Reduced 61.76%	10,400 $342,000
Q2 2020 Aug 14, 2020	BUY	$27.21 - $41.0 $740,112 - $1.12 Million	27,200 New	27,200 $744,000
Q1 2020 May 15, 2020	SELL	$19.54 - $38.85 $781,600 - $1.55 Million	-40,000 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$17.95 - $29.41 $718,000 - $1.18 Million	40,000 New	40,000 $1.11 Million

331

246M

3.95M

1.8M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $843M
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.